GlassScriptPhysician profile
Garry Tim Miller
NPI 1053568592
$13,824.69
in general payments reported to CMS, 2019-2025
59 companies · $1,755 in 2025
The $1,755 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,215 · 2020: $1,889 · 2021: $2,048 · 2022: $1,928 · 2023: $1,966 · 2024: $2,024 · 2025: $1,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,598 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,597.61 |
| Education | $146.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,829.19 | 2021-2025 | |
| Novo Nordisk INC | $1,368.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,167.55 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Astellas Pharma US INC | $894.12 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $859.60 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $773.86 | 2019-2023 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $715.26 | 2019-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $550.31 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Janssen Pharmaceuticals, INC | $544.07 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $458.72 | 2019-2024 | |
| Allergan, INC. | $415.30 | 2019-2020 | |
| Mylan Specialty L.P. | $384.83 | 2019-2024 | Yupelri |
| Axsome Therapeutics, INC. | $301.38 | 2023-2025 | Auvelity, Sunosi |
| Novartis Pharmaceuticals Corporation | $278.88 | 2019-2025 | |
| Glaxosmithkline, LLC. | $262.21 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garry Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.